Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
Launched by BRISTOL-MYERS SQUIBB · Jul 26, 2010
Trial Information
Current as of May 23, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subjects chronically infected with HCV genotype 1
- • Non-responder to prior therapy with peginterferon alfa and ribavirin
- • HCV RNA viral load of 100,00 IU/mL
- • Results of a liver biopsy ≤ 24 months prior to randomization consistent with chronic HCV infection; for compensated cirrhotics can be any time prior to randomization (compensated cirrhotics biopsy enrollment will be capped at 25% of randomized study population)
- • Ultrasound, CT scan or MRI results 12 months prior to randomization that do not demonstrate hepatocellular carcinoma
- • Body Mass Index (BMI) of 18 to 35 kg/m2
- Exclusion Criteria:
- • Positive for Hepatitis B infection (HBsAg) or HIV-1/HIV-2 antibody at screening
- • Evidence of medical condition associated with chronic liver disease other than HCV
- • Evidence of decompensated cirrhosis based on radiologic criteria or biopsy
About Bristol Myers Squibb
Bristol-Myers Squibb (BMS) is a global biopharmaceutical company dedicated to discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. With a robust portfolio of products across multiple therapeutic areas, including oncology, immunology, cardiovascular, and fibrotic diseases, BMS emphasizes cutting-edge research and a commitment to advancing medical science through clinical trials. The company is driven by a mission to provide transformative therapies, leveraging collaboration and scientific expertise to address unmet medical needs and improve patient outcomes worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Rochester, New York, United States
La Jolla, California, United States
New Orleans, Louisiana, United States
Indianapolis, Indiana, United States
St. Louis, Missouri, United States
Nashville, Tennessee, United States
San Francisco, California, United States
Tulsa, Oklahoma, United States
Fairfax, Virginia, United States
Baltimore, Maryland, United States
New Haven, Connecticut, United States
Clichy Cedex, , France
San Francisco, California, United States
Hannover, , Germany
Clayton, Victoria, Australia
Heidelberg, Victoria, Australia
Paris Cedex 14, , France
Nice Cedex 03, , France
Creteil Cedex, , France
Vandoeuvre Les Nancy, , France
South Miami, Florida, United States
Essen, , Germany
Madison, Wisconsin, United States
Providence, Rhode Island, United States
Frankfurt, , Germany
Edmonton, Alberta, Canada
Monterrey, Nuevo Leon, Mexico
San Antonio, Texas, United States
Montgomery, Alabama, United States
Perth, Western Australia, Australia
San Francisco, California, United States
Hamburg, , Germany
Guadalajara, Jalisco, Mexico
Cuernavaca, Morelos, Mexico
Fremantle, Western Australia, Australia
Vancouver, British Columbia, Canada
Hvidovre, , Denmark
Baltimore, Maryland, United States
Ciudad De Buenos Aires, Buenos Aires, Argentina
Prahan, Victoria, Australia
Toronto, Ontario, Canada
Randwick, New South Wales, Australia
Odense, , Denmark
Pavia, , Italy
Albany, New York, United States
San Diego, California, United States
Lyon Cedex 04, , France
Paris Cedex, , France
Houston, Texas, United States
Statesville, North Carolina, United States
Arlington, Texas, United States
San Juan, , Puerto Rico
Springfield, Massachusetts, United States
Bronx, New York, United States
Prov De Santa Fe, Santa Fe, Argentina
Los Angeles, California, United States
Aurora, Colorado, United States
Great Neck, New York, United States
Monticello, New York, United States
Houston, Texas, United States
Victoria, British Columbia, Canada
Aarhus, , Denmark
Cisanello (Pisa), , Italy
Gothenburg, , Sweden
Gainesville, Florida, United States
Lutherville, Maryland, United States
Chapel Hill, North Carolina, United States
Ponce, , Puerto Rico
Stockholm, , Sweden
Patients applied
Trial Officials
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials